(thirdQuint)The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC.

 This study is a prospective, randomized, open-label study.

 The CHB subjects who are cirrhosis will be randomized to two groups.

 The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,1801/2g/week for 48 weeks.

 The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.

.

 The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC@highlight

The CHB subjects who are cirrhosis, will be randomized to two groups.

 The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,1801/2g/week for 48 weeks.

 The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.

